Supplier
Annapolis Rheumatology LLC
Annapolis Rheumatology LLC was paid $1.07M by Medicaid between Jan 2018 and Nov 2024, across 10 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 57% of everything it billed.
33Billing provider infoANNAPOLIS RHEUMATOLOGY LLC
ANNAPOLIS, MD 21401
ANNAPOLIS, MD 21401
33aNPI1104188424assigned 06/12/2012
33bProvider typeNon-Pharmacy Dispensing Site
28Total paid$1.07M
24GClaims9,771
24DCodes billed10
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Non-Pharmacy Dispensing Site providers in Maryland
Rank by total paid#4 of 9
Median peer was paid$554K
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 257 | $19K | |
| 2019 | 300 | $15K | |
| 2020 | 850 | $65K | |
| 2021 | 1,570 | $174K | |
| 2022 | 2,003 | $229K | |
| 2023 | 2,660 | $297K | |
| 2024incomplete | 2,131 | $269K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 57% | 7,386 | 6,793 | $610K |
| 96401 | 29% | 760 | 669 | $309K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 8.6% | 252 | 224 | $92K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.5% | 141 | 131 | $16K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.4% | 375 | 353 | $15K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 1.4% | 423 | 392 | $15K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 31 | 28 | $5K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 13 | 13 | $2K |
| 76881 | <1% | 25 | 25 | $2K | |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 0% | 365 | 324 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJACOB, ASHOK (MANGING DIRECTOR)